A tumor suppressor role for C/EBPα in solid tumors: More than fat and blood

Oncogene

Volumn 36, Issue 37, 2017, Pages 5221-5230

  Lourenco A R ^a   Coffer, P J ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CCAAT ENHANCER BINDING PROTEIN ALPHA;

APOPTOSIS; CELL GROWTH; CELL MIGRATION; CELL STRESS; CELL SURVIVAL; CELLULAR DISTRIBUTION; EPIGENETICS; GENE EXPRESSION; GENE MUTATION; GENETIC HETEROGENEITY; GENETIC REGULATION; HUMAN; METASTASIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN PROCESSING; REVIEW; SOLID MALIGNANT NEOPLASM; TUMOR SUPPRESSOR GENE; ANIMAL; BLOOD; CELL DIFFERENTIATION; GENETICS; METABOLISM; NEOPLASM; PATHOLOGY;

ANIMALS; CCAAT-ENHANCER-BINDING PROTEIN-ALPHA; CELL DIFFERENTIATION; GENES, TUMOR SUPPRESSOR; HUMANS; NEOPLASMS;

EID: 85031695785     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2017.151     Document Type: Review

References (147)

1. Johnson PF. Molecular stop signs: regulation of cell-cycle arrest by C/EBP transcription factors. J Cell Sci 2005; 118: 2545-2555.
2. Osada S, Yamamoto H, Nishihara T, Imagawa M. DNA binding specificity of the CCAAT/enhancer-binding protein transcription factor family. J Biol Chem 1996; 271: 3891-3896.
3. Gombart AF, Hofmann W-K, Kawano S, Takeuchi S, Krug U, Kwok SH et al. Mutations in the gene encoding the transcription factor CCAAT/enhancer binding protein alpha in myelodysplastic syndromes and acute myeloid leukemias. Blood 2002; 99: 1332-1340.
4. Miller M, Shuman JD, Sebastian T, Dauter Z, Johnson PF. Structural basis for DNA recognition by the basic region leucine zipper transcription factor CCAAT/enhancer-binding protein alpha. J Biol Chem 2003; 278: 15178-15184.
5. Graves BJ, Johnson PF, McKnight SL. Homologous recognition of a promoter domain common to the MSV LTR and the HSV tk gene. Cell 1986; 44: 565-576.
6. Calkhoven CF, Müller C, Leutz A. Translational control of C/EBPalpha and C/EBPbeta isoform expression. Genes Dev 2000; 14: 1920-1932.
7. Descombes P, Schibler U. A liver-enriched transcriptional activator protein, LAP, and a transcriptional inhibitory protein, LIP, are translated from the same mRNA. Cell 1991; 67: 569-579.
8. Lin FT, MacDougald OA, Diehl AM, Lane MD. A 30-kDa alternative translation product of the CCAAT/enhancer binding protein alpha message: transcriptional activator lacking antimitotic activity. Proc Natl Acad Sci USA 1993; 90: 9606-9610.
9. Ossipow V, Descombes P, Schibler U. CCAAT/enhancer-binding protein mRNA is translated into multiple proteins with different transcription activation potentials. Proc Natl Acad Sci USA 1993; 90: 8219-8223.
10. Nerlov C, Ziff EB. CCAAT/enhancer binding protein-alpha amino acid motifs with dual TBP and TFIIB binding ability co-operate to activate transcription in both yeast and mammalian cells. EMBO J 1995; 14: 4318-4328.
11. Porse BT, Pedersen TA, Xu X, Lindberg B, Wewer UM, Friis-Hansen L et al. E2F repression by C/EBPalpha is required for adipogenesis and granulopoiesis in vivo. Cell 2001; 107: 247-258.
12. Zaragoza K, Bégay V, Schuetz A, Heinemann U, Leutz A. Repression of transcriptional activity of C/EBPalpha by E2F-dimerization partner complexes. Mol Cell Biol 2010; 30: 2293-2304.
13. D'Alo' F, Johansen LM, Nelson EA, Radomska HS, Evans EK, Zhang P et al. The amino terminal and E2F interaction domains are critical for C/EBP alphamediated induction of granulopoietic development of hematopoietic cells. Blood 2003; 102: 3163-3171.
14. Pabst T, Mueller BU, Zhang P, Radomska HS, Narravula S, Schnittger S et al. Dominant-negative mutations of CEBPA, encoding CCAAT/enhancer binding protein-alpha (C/EBPalpha), in acute myeloid leukemia. Nat Genet 2001; 27: 263-270.
15. Kato N, Kitaura J, Doki N, Komeno Y, Watanabe-Okochi N, Togami K et al. Two types of C/EBPα mutations play distinct but collaborative roles in leukemogenesis: lessons from clinical data and BMT models. Blood 2011; 117: 221-233.
16. Roe J-S, Vakoc CR. C/EBPα: critical at the origin of leukemic transformation. J Exp Med 2014; 211: 1-4.
17. Anand S, Ebner J, Warren CB, Raam MS, Piliang M, Billings SD et al. C/EBP transcription factors in human squamous cell carcinoma: selective changes in expression of isoforms correlate with the neoplastic state. PLoS One 2014; 9: e112073.
18. Bennett KL, Hackanson B, Smith LT, Morrison CD, Lang JC, Schuller DE et al. Tumor suppressor activity of CCAAT/enhancer binding protein alpha is epigenetically down-regulated in head and neck squamous cell carcinoma. Cancer Res 2007; 67: 4657-4664.
19. Datta J, Majumder S, Kutay H, Motiwala T, Frankel W, Costa R et al. Metallothionein expression is suppressed in primary human hepatocellular carcinomas and is mediated through inactivation of CCAAT/enhancer binding protein alpha by phosphatidylinositol 3-kinase signaling cascade. Cancer Res 2007; 67: 2736-2746.
20. Gery S, Tanosaki S, Bose S, Bose N, Vadgama J, Koeffler HP. Down-regulation and growth inhibitory role of C/EBPalpha in breast cancer. Clin Cancer Res 2005; 11: 3184-3190.
21. Lu G-D, Leung CH-W, Yan B, Tan CM-Y, Low SY, Aung MO et al. C/EBPalpha is upregulated in a subset of hepatocellular carcinomas and plays a role in cell growth and proliferation. Gastroenterology 2010; 139: 632-643, 643.e1-4.
22. Tada Y, Brena RM, Hackanson B, Morrison C, Otterson GA, Plass C. Epigenetic modulation of tumor suppressor CCAAT/enhancer binding protein alpha activity in lung cancer. J Natl Cancer Inst 2006; 98: 396-406.
23. Yin H, Radomska HS, Tenen DG, Glass J. Down regulation of PSA by C/EBPalpha is associated with loss of AR expression and inhibition of PSA promoter activity in the LNCaP cell line. BMC Cancer 2006; 6: 158.
24. Wu Y V, Okada T, DeCarolis P, Socci N, O'Connor R, Geha RC et al. Restoration of C/EBPα in dedifferentiated liposarcoma induces G2/M cell cycle arrest and apoptosis. Genes Chromosom Cancer 2012; 51: 313-327.
25. Flodby P, Barlow C, Kylefjord H, Ahrlund-Richter L, Xanthopoulos KG. Increased hepatic cell proliferation and lung abnormalities in mice deficient in CCAAT/enhancer binding protein alpha. J Biol Chem 1996; 271: 24753-24760.
26. Zhang DE, Zhang P, Wang ND, Hetherington CJ, Darlington GJ, Tenen DG. Absence of granulocyte colony-stimulating factor signaling and neutrophil development in CCAAT enhancer binding protein alpha-deficient mice. Proc Natl Acad Sci USA 1997; 94: 569-574.
27. Wang ND, Finegold MJ, Bradley A, Ou CN, Abdelsayed S V, Wilde MD et al. Impaired energy homeostasis in C/EBP alpha knockout mice. Science 1995; 269: 1108-1112.
28. Schuster MB, Porse BT. C/EBPalpha: a tumour suppressor in multiple tissues? Biochim Biophys Acta 2006; 1766: 88-103.
29. Oh HS, Smart RC. Expression of CCAAT/enhancer binding proteins (C/EBP) is associated with squamous differentiation in epidermis and isolated primary keratinocytes and is altered in skin neoplasms. J Invest Dermatol 1998; 110: 939-945.
30. Birkenmeier EH, Gwynn B, Howard S, Jerry J, Gordon JI, Landschulz WH et al. Tissue-specific expression, developmental regulation, and genetic mapping of the gene encoding CCAAT/enhancer binding protein. Genes Dev 1989; 3: 1146-1156.
31. Antonson P, Xanthopoulos KG. Molecular cloning, sequence, and expression patterns of the human gene encoding CCAAT/enhancer binding protein alpha (C/EBP alpha). Biochem Biophys Res Commun 1995; 215: 106-113.
32. Hohaus S, Petrovick MS, Voso MT, Sun Z, Zhang DE, Tenen DG. PU.1 (Spi-1) and C/EBP alpha regulate expression of the granulocyte-macrophage colony-stimulating factor receptor alpha gene. Mol Cell Biol 1995; 15: 5830-5845.
33. Lefterova MI, Zhang Y, Steger DJ, Schupp M, Schug J, Cristancho A et al. PPARgamma and C/EBP factors orchestrate adipocyte biology via adjacent binding on a genome-wide scale. Genes Dev 2008; 22: 2941-2952.
34. McNagny KM, Sieweke MH, Döderlein G, Graf T, Nerlov C. Regulation of eosinophil-specific gene expression by a C/EBP-Ets complex and GATA-1. EMBO J 1998; 17: 3669-3680.
35. Cassel TN, Suske G, Nord M. C/EBP alpha and TTF-1 synergistically transactivate the Clara cell secretory protein gene. Ann N Y Acad Sci 2000; 923: 300-302.
36. Pedersen TA, Kowenz-Leutz E, Leutz A, Nerlov C. Cooperation between C/EBPalpha TBP/TFIIB and SWI/SNF recruiting domains is required for adipocyte differentiation. Genes Dev 2001; 15: 3208-3216.
37. Erickson RL, Hemati N, Ross SE, MacDougald OA. p300 coactivates the adipogenic transcription factor CCAAT/enhancer-binding protein alpha. J Biol Chem 2001; 276: 16348-16355.
38. Schaufele F, Enwright JF, Wang X, Teoh C, Srihari R, Erickson R et al. CCAAT/enhancer binding protein alpha assembles essential cooperating factors in common subnuclear domains. Mol Endocrinol 2001; 15: 1665-1676.
39. Rosen ED, Walkey CJ, Puigserver P, Spiegelman BM. Transcriptional regulation of adipogenesis. Genes Dev 2000; 14: 1293-1307.
40. Wang QA, Tao C, Jiang L, Shao M, Ye R, Zhu Y et al. Distinct regulatory mechanisms governing embryonic versus adult adipocyte maturation. Nat Cell Biol 2015; 17: 1099-1111.
41. Zhang P, Iwama A, Datta MW, Darlington GJ, Link DC, Tenen DG. Upregulation of interleukin 6 and granulocyte colony-stimulating factor receptors by transcription factor CCAAT enhancer binding protein alpha (C/EBP alpha) is critical for granulopoiesis. J Exp Med 1998; 188: 1173-1184.
42. Radomska HS, Huettner CS, Zhang P, Cheng T, Scadden DT, Tenen DG. CCAAT/enhancer binding protein alpha is a regulatory switch sufficient for induction of granulocytic development from bipotential myeloid progenitors. Mol Cell Biol 1998; 18: 4301-4314.
43. Zhang DE, Hetherington CJ, Meyers S, Rhoades KL, Larson CJ, Chen HM et al. CCAAT enhancer-binding protein (C/EBP) and AML1 (CBF alpha2) synergistically activate the macrophage colony-stimulating factor receptor promoter. Mol Cell Biol 1996; 16: 1231-1240.
44. Zhang P, Iwasaki-Arai J, Iwasaki H, Fenyus ML, Dayaram T, Owens BM et al. Enhancement of hematopoietic stem cell repopulating capacity and self-renewal in the absence of the transcription factor C/EBP alpha. Immunity 2004; 21: 853-863.
45. Leroy H, Roumier C, Huyghe P, Biggio V, Fenaux P, Preudhomme C. CEBPA point mutations in hematological malignancies. Leukemia 2005; 19: 329-334.
46. Nerlov C. C/EBPalpha mutations in acute myeloid leukaemias. Nat Rev Cancer 2004; 4: 394-400.
47. Sato A, Yamada N, Ogawa Y, Ikegami M. CCAAT/enhancer-binding protein-α suppresses lung tumor development in mice through the p38α MAP kinase pathway. PLoS One 2013; 8: e57013.
48. Halmos B, Huettner CS, Kocher O, Ferenczi K, Karp DD, Tenen DG. Downregulation and antiproliferative role of C/EBPalpha in lung cancer. Cancer Res 2002; 62: 528-534.
49. Bassères DS, Levantini E, Ji H, Monti S, Elf S, Dayaram T et al. Respiratory failure due to differentiation arrest and expansion of alveolar cells following lungspecific loss of the transcription factor C/EBPalpha in mice. Mol Cell Biol 2006; 26: 1109-1123.
50. Seagroves TN, Krnacik S, Raught B, Gay J, Burgess-Beusse B, Darlington GJ et al. C/EBPbeta, but not C/EBPalpha, is essential for ductal morphogenesis, lobuloalveolar proliferation, and functional differentiation in the mouse mammary gland. Genes Dev 1998; 12: 1917-1928.
51. Tseng H-H, Hwang Y-H, Yeh K-T, Chang J-G, Chen Y-L, Yu H-S. Reduced expression of C/EBP alpha protein in hepatocellular carcinoma is associated with advanced tumor stage and shortened patient survival. J Cancer Res Clin Oncol 2009; 135: 241-247.
52. Tomizawa M, Wang Y-Q, Ebara M, Saisho H, Watanabe K, Nakagawara A et al. Decreased expression of the CCAAT/enhancer binding protein alpha gene involved in hepatocyte proliferation in human hepatocellular carcinomas. Int J Mol Med 2002; 9: 597-600.
53. Shim M, Powers KL, Ewing SJ, Zhu S, Smart RC. Diminished expression of C/EBPalpha in skin carcinomas is linked to oncogenic Ras and reexpression of C/EBPalpha in carcinoma cells inhibits proliferation. Cancer Res 2005; 65: 861-867.
54. Costa DB, Li S, Kocher O, Feins RH, Keller SM, Schiller JH et al. Immunohistochemical analysis of C/EBPalpha in non-small cell lung cancer reveals frequent down-regulation in stage II and IIIA tumors: a correlative study of E3590. Lung Cancer 2007; 56: 97-103.
55. Pan Z, Zheng W, Zhang J, Gao R, Li D, Guo X et al. Down-regulation of the expression of CCAAT/enhancer binding protein α gene in cervical squamous cell carcinoma. BMC Cancer 2014; 14: 417.
56. Shi D-B, Wang Y-W, Xing A-Y, Gao J-W, Zhang H, Guo X-Y et al. C/EBPα-induced miR-100 expression suppresses tumor metastasis and growth by targeting ZBTB7A in gastric cancer. Cancer Lett 2015; 369: 376-385.
57. Takai N, Kawamata N, Walsh CS, Gery S, Desmond JC, Whittaker S et al. Discovery of epigenetically masked tumor suppressor genes in endometrial cancer. Mol Cancer Res 2005; 3: 261-269.
58. Tomizawa M, Watanabe K, Saisho H, Nakagawara A, Tagawa M. Down-regulated expression of the CCAAT/enhancer binding protein alpha and beta genes in human hepatocellular carcinoma: a possible prognostic marker. Anticancer Res 2003; 23: 351-354.
59. Roepman P, Wessels LFA, Kettelarij N, Kemmeren P, Miles AJ, Lijnzaad P et al. An expression profile for diagnosis of lymph node metastases from primary head and neck squamous cell carcinomas. Nat Genet 2005; 37: 182-186.
60. Wang C, Ren R, Hu H, Tan C, Han M, Wang X et al. MiR-182 is up-regulated and targeting Cebpa in hepatocellular carcinoma. Chin J Cancer Res 2014; 26: 17-29.
61. Seifeddine R, Dreiem A, Blanc E, Fulchignoni-Lataud M-C, Le Frère Belda M-A, Lecuru F et al. Hypoxia down-regulates CCAAT/enhancer binding protein-alpha expression in breast cancer cells. Cancer Res 2008; 68: 2158-2165.
62. Eales KL, Hollinshead KER, Tennant DA. Hypoxia and metabolic adaptation of cancer cells. Oncogenesis 2016; 5: e190.
63. Loomis KD, Zhu S, Yoon K, Johnson PF, Smart RC. Genetic ablation of CCAAT/enhancer binding protein alpha in epidermis reveals its role in suppression of epithelial tumorigenesis. Cancer Res 2007; 67: 6768-6776.
64. Zhang S, Jiang T, Feng L, Sun J, Lu H, Wang Q et al. Yin Yang-1 suppresses differentiation of hepatocellular carcinoma cells through the downregulation of CCAAT/enhancer-binding protein alpha. J Mol Med 2012; 90: 1069-1077.
65. Foka P, Singh NN, Salter RC, Ramji DP. The tumour necrosis factor-alphamediated suppression of the CCAAT/enhancer binding protein-alpha gene transcription in hepatocytes involves inhibition of autoregulation. Int J Biochem Cell Biol 2009; 41: 1189-1197.
66. Ventura JJ, Tenbaum S, Perdiguero E, Huth M, Guerra C, Barbacid M et al. p38alpha MAP kinase is essential in lung stem and progenitor cell proliferation and differentiation. Nat Genet 2007; 39: 750-758.
67. Oeztuerk-Winder F, Guinot A, Ochalek A, Ventura J-J. Regulation of human lung alveolar multipotent cells by a novel p38α MAPK/miR-17-92 axis. EMBO J 2012; 31: 3431-3441.
68. Zhang J, Wilkinson JE, Gonit M, Keck R, Selman S, Ratnam M. Expression and subcellular localization of the CCAAT/enhancer binding protein alpha in relation to postnatal development and malignancy of the prostate. Prostate 2008; 68: 1206-1214.
69. Kumagai T, Akagi T, Desmond JC, Kawamata N, Gery S, Imai Y et al. Epigenetic regulation and molecular characterization of C/EBPalpha in pancreatic cancer cells. Int J Cancer 2009; 124: 827-833.
70. Zhang J, Gonit M, Salazar MD, Shatnawi A, Shemshedini L, Trumbly R et al. C/EBPalpha redirects androgen receptor signaling through a unique bimodal interaction. Oncogene 2010; 29: 723-738.
71. Chattopadhyay S, Gong E-Y, Hwang M, Park E, Lee HJ, Hong CY et al. The CCAAT enhancer-binding protein-alpha negatively regulates the transactivation of androgen receptor in prostate cancer cells. Mol Endocrinol 2006; 20: 984-995.
72. Gaykalova DA, Mambo E, Choudhary A, Houghton J, Buddavarapu K, Sanford T et al. Novel insight into mutational landscape of head and neck squamous cell carcinoma. PLoS One 2014; 9: e93102.
73. Costa DB, Dayaram T, D'Alo F, Wouters BJ, Tenen DG, Meyerson M et al. C/EBP alpha mutations in lung cancer. Lung Cancer 2006; 53: 253-254.
74. Barretina J, Taylor BS, Banerji S, Ramos AH, Lagos-Quintana M, Decarolis PL et al. Subtype-specific genomic alterations define new targets for soft-tissue sarcoma therapy. Nat Genet 2010; 42: 715-721.
75. Girard L, Zöchbauer-Müller S, Virmani AK, Gazdar AF, Minna JD. Genome-wide allelotyping of lung cancer identifies new regions of allelic loss, differences between small cell lung cancer and non-small cell lung cancer, and loci clustering. Cancer Res 2000; 60: 4894-4906.
76. Jenuwein T, Allis CD. Translating the histone code. Science 2001; 293: 1074-1080.
77. Bernstein BE, Meissner A, Lander ES. The mammalian epigenome. Cell 2007; 128: 669-681.
78. Esteller M, Silva JM, Dominguez G, Bonilla F, Matias-Guiu X, Lerma E et al. Promoter hypermethylation and BRCA1 inactivation in sporadic breast and ovarian tumors. J Natl Cancer Inst 2000; 92: 564-569.
79. Kang JH, Kim SJ, Noh DY, Park IA, Choe KJ, Yoo OJ et al. Methylation in the p53 promoter is a supplementary route to breast carcinogenesis: correlation between CpG methylation in the p53 promoter and the mutation of the p53 gene in the progression from ductal carcinoma in situ to invasive ductal carcinoma. Lab Invest 2001; 81: 573-579.
80. Esteller M, Toyota M, Sanchez-Cespedes M, Capella G, Peinado MA, Watkins DN et al. Inactivation of the DNA repair gene O6-methylguanine-DNA methyltransferase by promoter hypermethylation is associated with G to A mutations in K-ras in colorectal tumorigenesis. Cancer Res 2000; 60: 2368-2371.
81. Taylor BS, DeCarolis PL, Angeles C V, Brenet F, Schultz N, Antonescu CR et al. Frequent alterations and epigenetic silencing of differentiation pathway genes in structurally rearranged liposarcomas. Cancer Discov 2011; 1: 587-597.
82. Bennett KL, Romigh T, Arab K, Teresi RE, Tada Y, Eng C et al. Activator protein 2 alpha (AP2alpha) suppresses 42 kDa C/CAAT enhancer binding protein alpha (p42(C/EBPalpha)) in head and neck squamous cell carcinoma. Int J Cancer 2009; 124: 1285-1292.
83. Lin T-C, Hou H, Chou W-C, Ou D-L, Yu S-L, Tien H-F et al. CEBPA methylation as a prognostic biomarker in patients with de novo acute myeloid leukemia. Leukemia 2011; 25: 32-40.
84. Sugahara K, Iyama KI, Kimura T, Sano K, Darlington GJ, Akiba T et al. Mice lacking CCAAt/enhancer-binding protein-alpha show hyperproliferation of alveolar type II cells and increased surfactant protein mRNAs. Cell Tissue Res 2001; 306: 57-63.
85. Soriano HE, Kang DC, Finegold MJ, Hicks MJ, Wang ND, Harrison W et al. Lack of C/EBP alpha gene expression results in increased DNA synthesis and an increased frequency of immortalization of freshly isolated mice [correction of rat] hepatocytes. Hepatology 1998; 27: 392-401.
86. Yoon K, Smart RC. C/EBPalpha is a DNA damage-inducible p53-regulated mediator of the G1 checkpoint in keratinocytes. Mol Cell Biol 2004; 24: 10650-10660.
87. Thompson EA, Zhu S, Hall JR, House JS, Ranjan R, Burr JA et al. C/EBPα expression is downregulated in human nonmelanoma skin cancers and inactivation of C/EBPα confers susceptibility to UVB-induced skin squamous cell carcinomas. J Invest Dermatol 2011; 131: 1339-1346.
88. Raught B, Liao WS, Rosen JM. Developmentally and hormonally regulated CCAAT/enhancer-binding protein isoforms influence beta-casein gene expression. Mol Endocrinol 1995; 9: 1223-1232.
89. Lopez RG, Garcia-Silva S, Moore SJ, Bereshchenko O, Martinez-Cruz AB, Ermakova O et al. C/EBPalpha and beta couple interfollicular keratinocyte proliferation arrest to commitment and terminal differentiation. Nat Cell Biol 2009; 11: 1181-1190.
90. Shi Y-C, Zhao H, Yin C, Zeng X, Zhang Q, Xu W-P et al. C/EBPα inhibits hepatocellular carcinoma by reducing Notch3/Hes1/p27 cascades. Dig Liver Dis 2013; 45: 844-851.
91. Watkins PJ, Condreay JP, Huber BE, Jacobs SJ, Adams DJ. Impaired proliferation and tumorigenicity induced by CCAAT/enhancer-binding protein. Cancer Res 1996; 56: 1063-1067.
92. Tan EH, Hooi SC, Laban M, Wong E, Ponniah S, Wee A et al. CCAAT/enhancer binding protein alpha knock-in mice exhibit early liver glycogen storage and reduced susceptibility to hepatocellular carcinoma. Cancer Res 2005; 65: 10330-10337.
93. Huan H, Wen X, Chen X, Wu L, Liu W, Habib NA et al. C/EBPα short-activating RNA suppresses metastasis of hepatocellular carcinoma through inhibiting EGFR/β-catenin signaling mediated EMT. PLoS One 2016; 11: e0153117.
94. Reebye V, Saetrom P, Mintz PJ, Huang K-W, Swiderski P, Peng L et al. Novel RNA oligonucleotide improves liver function and inhibits liver carcinogenesis in vivo. Hepatology 2014; 59: 216-227.
95. Yoon S, Huang K-W, Reebye V, Mintz P, Tien Y-W, Lai H-S et al. Targeted delivery of C/EBPα -saRNA by pancreatic ductal adenocarcinoma (PDAC)-specific RNA aptamers Inhibits Tumor Growth in vivo. Mol Ther 2016; 24: 1106-1116.
96. Dhawan P, Wieder R, Weider R, Christakos S. CCAAT enhancer-binding protein alpha is a molecular target of 1, 25-dihydroxyvitamin D3 in MCF-7 breast cancer cells. J Biol Chem 2009; 284: 3086-3095.
97. Saramäki A, Banwell CM, Campbell MJ, Carlberg C. Regulation of the human p21 (waf1/cip1) gene promoter via multiple binding sites for p53 and the vitamin D3 receptor. Nucleic Acids Res 2006; 34: 543-554.
98. Zeng C, Wang R, Li D, Lin X-J, Wei Q-K, Yuan Y et al. A novel GSK-3 beta-C/EBP alpha-miR-122-insulin-like growth factor 1 receptor regulatory circuitry in human hepatocellular carcinoma. Hepatology 2010; 52: 1702-1712.
99. Kimura SH, Nojima H. Cyclin G1 associates with MDM2 and regulates accumulation and degradation of p53 protein. Genes Cells 2002; 7: 869-880.
100. Fornari F, Gramantieri L, Giovannini C, Veronese A, Ferracin M, Sabbioni S et al. MiR-122/cyclin G1 interaction modulates p53 activity and affects doxorubicin sensitivity of human hepatocarcinoma cells. Cancer Res 2009; 69: 5761-5767.
101. el-Deiry WS, Harper JW, O'Connor PM, Velculescu VE, Canman CE, Jackman J et al. WAF1/CIP1 is induced in p53-mediated G1 arrest and apoptosis. Cancer Res 1994; 54: 1169-1174.
102. Timchenko NA, Harris TE, Wilde M, Bilyeu TA, Burgess-Beusse BL, Finegold MJ et al. CCAAT/enhancer binding protein alpha regulates p21 protein and hepatocyte proliferation in newborn mice. Mol Cell Biol 1997; 17: 7353-7361.
103. Halmos B, Bassères DS, Monti S, D'Aló F, Dayaram T, Ferenczi K et al. A transcriptional profiling study of CCAAT/enhancer binding protein targets identifies hepatocyte nuclear factor 3 beta as a novel tumor suppressor in lung cancer. Cancer Res 2004; 64: 4137-4147.
104. Murata K, Hattori M, Hirai N, Shinozuka Y, Hirata H, Kageyama R et al. Hes1 directly controls cell proliferation through the transcriptional repression of p27Kip1. Mol Cell Biol 2005; 25: 4262-4271.
105. Wang G-L, Shi X, Salisbury E, Sun Y, Albrecht JH, Smith RG et al. Cyclin D3 maintains growth-inhibitory activity of C/EBPalpha by stabilizing C/EBPalphacdk2 and C/EBPalpha-Brm complexes. Mol Cell Biol 2006; 26: 2570-2582.
106. Wang H, Iakova P, Wilde M, Welm A, Goode T, Roesler WJ et al. C/EBPalpha arrests cell proliferation through direct inhibition of Cdk2 and Cdk4. Mol Cell 2001; 8: 817-828.
107. Wang G-L, Shi X, Haefliger S, Jin J, Major A, Iakova P et al. Elimination of C/EBPalpha through the ubiquitin-proteasome system promotes the development of liver cancer in mice. J Clin Invest 2010; 120: 2549-2562.
108. Wang G-L, Iakova P, Wilde M, Awad S, Timchenko NA. Liver tumors escape negative control of proliferation via PI3K/Akt-mediated block of C/EBP alpha growth inhibitory activity. Genes Dev 2004; 18: 912-925.
109. Wang G-L, Timchenko NA. Dephosphorylated C/EBPalpha accelerates cell proliferation through sequestering retinoblastoma protein. Mol Cell Biol 2005; 25: 1325-1338.
110. Yin H, Lowery M, Glass J. In prostate cancer C/EBPalpha promotes cell growth by the loss of interactions with CDK2, CDK4, and E2F and by activation of AKT. Prostate 2009; 69: 1001-1016.
111. Grandinetti KB, Stevens TA, Ha S, Salamone RJ, Walker JR, Zhang J et al. Overexpression of TRIB2 in human lung cancers contributes to tumorigenesis through downregulation of C/EBPα. Oncogene 2011; 30: 3328-3335.
112. Keeshan K, He Y, Wouters BJ, Shestova O, Xu L, Sai H et al. Tribbles homolog 2 inactivates C/EBPalpha and causes acute myelogenous leukemia. Cancer Cell 2006; 10: 401-411.
113. Higashitsuji H, Higashitsuji H, Itoh K, Sakurai T, Nagao T, Sumitomo Y et al. The oncoprotein gankyrin binds to MDM2/HDM2, enhancing ubiquitylation and degradation of p53. Cancer Cell 2005; 8: 75-87.
114. Kim YH, Kim J-H, Choi YW, Lim SK, Yim H, Kang SY et al. Gankyrin is frequently overexpressed in breast cancer and is associated with ErbB2 expression. Exp Mol Pathol 2013; 94: 360-365.
115. Li J, Knobloch TJ, Kresty LA, Zhang Z, Lang JC, Schuller DE et al. Gankyrin, a biomarker for epithelial carcinogenesis, is overexpressed in human oral cancer. Anticancer Res 2011; 31: 2683-2692.
116. Tang S, Yang G, Meng Y, Du R, Li X, Fan R et al. Overexpression of a novel gene gankyrin correlates with the malignant phenotype of colorectal cancer. Cancer Biol Ther 2010; 9: 88-95.
117. Zhao Y, Jian W, Gao W, Zheng Y-X, Wang Y-K, Zhou Z-Q et al. RNAi silencing of c-Myc inhibits cell migration, invasion, and proliferation in HepG2 human hepatocellular carcinoma cell line: c-Myc silencing in hepatocellular carcinoma cell. Cancer Cell Int 2013; 13: 23.
118. Wolfer A, Wittner BS, Irimia D, Flavin RJ, Lupien M, Gunawardane RN et al. MYC regulation of a 'poor-prognosis' metastatic cancer cell state. Proc Natl Acad Sci USA 2010; 107: 3698-3703.
119. Cappellen D, Schlange T, Bauer M, Maurer F, Hynes NE. Novel c-MYC target genes mediate differential effects on cell proliferation and migration. EMBO Rep 2007; 8: 70-76.
120. Kim J, Gao P, Liu Y-C, Semenza GL, Dang CV. Hypoxia-inducible factor 1 and dysregulated c-Myc cooperatively induce vascular endothelial growth factor and metabolic switches hexokinase 2 and pyruvate dehydrogenase kinase 1. Mol Cell Biol 2007; 27: 7381-7393.
121. Ma L, Young J, Prabhala H, Pan E, Mestdagh P, Muth D et al. miR-9, a MYC/MYCNactivated microRNA, regulates E-cadherin and cancer metastasis. Nat Cell Biol 2010; 12: 247-256.
122. Song L-B, Li J, Liao W-T, Feng Y, Yu C-P, Hu L-J et al. The polycomb group protein Bmi-1 represses the tumor suppressor PTEN and induces epithelialmesenchymal transition in human nasopharyngeal epithelial cells. J Clin Invest 2009; 119: 3626-3636.
123. Guo B-H, Feng Y, Zhang R, Xu L-H, Li M-Z, Kung H-F et al. Bmi-1 promotes invasion and metastasis, and its elevated expression is correlated with an advanced stage of breast cancer. Mol Cancer 2011; 10: 10.
124. Mori S, Chang JT, Andrechek ER, Matsumura N, Baba T, Yao G et al. Anchorageindependent cell growth signature identifies tumors with metastatic potential. Oncogene 2009; 28: 2796-2805.
125. Johansen LM, Iwama A, Lodie TA, Sasaki K, Felsher DW, Golub TR et al. c-Myc is a critical target for c/EBPalpha in granulopoiesis. Mol Cell Biol 2001; 21: 3789-3806.
126. Jeon B-N, Yoo J-Y, Choi W-I, Lee C-E, Yoon H-G, Hur M-W. Proto-oncogene FBI-1 (Pokemon/ZBTB7A) represses transcription of the tumor suppressor Rb gene via binding competition with Sp1 and recruitment of co-repressors. J Biol Chem 2008; 283: 33199-33210.
127. Ozenne P, Eymin B, Brambilla E, Gazzeri S. The ARF tumor suppressor: Structure, functions and status in cancer. Int J Cancer 2010; 127: 2239-2247.
128. Cheng J, Yu D V, Zhou J-H, Shapiro DJ. Tamoxifen induction of CCAAT enhancerbinding protein alpha is required for tamoxifen-induced apoptosis. J Biol Chem 2007; 282: 30535-30543.
129. Wang G-L, Shi X, Salisbury E, Timchenko NA. Regulation of apoptotic and growth inhibitory activities of C/EBPalpha in different cell lines. Exp Cell Res 2008; 314: 1626-1639.
130. Zhang J, Ma Y, Wang S, Chen F, Gu Y. C/EBPα inhibits proliferation of breast cancer cells via a novel pathway of miR-134/CREB. Int J Clin Exp Pathol 2015; 8: 14472-14478.
131. Gao J, Wang W-Y, Mao Y-W, Gräff J, Guan J-S, Pan L et al. A novel pathway regulates memory and plasticity via SIRT1 and miR-134. Nature 2010; 466: 1105-1109.
132. Sun C-C, Li S-J, Li D-J. Hsa-miR-134 suppresses non-small cell lung cancer (NSCLC) development through down-regulation of CCND1. Oncotarget 2016; 7: 35960-35978.
133. Maass N, Biallek M, Rösel F, Schem C, Ohike N, Zhang M et al. Hypermethylation and histone deacetylation lead to silencing of the maspin gene in human breast cancer. Biochem Biophys Res Commun 2002; 297: 125-128.
134. Latha K, Zhang W, Cella N, Shi HY, Zhang M. Maspin mediates increased tumor cell apoptosis upon induction of the mitochondrial permeability transition. Mol Cell Biol 2005; 25: 1737-1748.
135. Liu J, Yin S, Reddy N, Spencer C, Sheng S. Bax mediates the apoptosis-sensitizing effect of maspin. Cancer Res 2004; 64: 1703-1711.
136. Patrick BA, Jaiswal AK. Stress-induced NQO1 controls stability of C/EBPα against 20S proteasomal degradation to regulate p63 expression with implications in protection against chemical-induced skin cancer. Oncogene 2012; 31: 4362-4371.
137. Lynes MA, Hidalgo J, Manso Y, Devisscher L, Laukens D, Lawrence DA. Metallothionein and stress combine to affect multiple organ systems. Cell Stress Chaperones 2014; 19: 605-611.
138. Ruttkay-Nedecky B, Nejdl L, Gumulec J, Zitka O, Masarik M, Eckschlager T et al. The role of metallothionein in oxidative stress. Int J Mol Sci 2013; 14: 6044-6066.
139. Yin H, Smith M, Glass J. Stable expression of C/EBPalpha in prostate cancer cells down-regulates metallothionein and increases zinc-induced toxicity. Prostate 2005; 62: 209-216.
140. House JS, Zhu S, Ranjan R, Linder K, Smart RC. C/EBPalpha and C/EBPbeta are required for Sebocyte differentiation and stratified squamous differentiation in adult mouse skin. PLoS One 2010; 5: e9837.
141. Chen SS, Chen JF, Johnson PF, Muppala V, Lee YH. C/EBPbeta, when expressed from the C/ebpalpha gene locus, can functionally replace C/EBPalpha in liver but not in adipose tissue. Mol Cell Biol 2000; 20: 7292-7299.
142. Milde-Langosch K, Löning T, Bamberger A-M. Expression of the CCAAT/enhancer- binding proteins C/EBPalpha, C/EBPbeta and C/EBPdelta in breast cancer: correlations with clinicopathologic parameters and cell-cycle regulatory proteins. Breast Cancer Res Treat 2003; 79: 175-185.
143. Hall JR, Bereman MS, Nepomuceno AI, Thompson EA, Muddiman DC, Smart RC. C/EBPα regulates CRL4(Cdt2)-mediated degradation of p21 in response to UVBinduced DNA damage to control the G1/S checkpoint. Cell Cycle 2014; 13: 3602-3610.
144. Tomizawa M, Horie H, Yamamoto H, Matsunaga T, Sasaki F, Hashizume K et al. Reciprocal expression of CCAAT/enhancer binding proteins alpha and beta in hepatoblastomas and its prognostic significance. Oncol Rep 2007; 17: 341-344.
145. Lu G-D, CH-W Leung, Yan B, CM-Y Tan, Low SY, Aung MO et al. C/EBPalpha is upregulated in a subset of hepatocellular carcinomas and plays a role in cell growth and proliferation. Gastroenterology 2010; 139: 632-643 643.e1.
146. Ming J, Zhou Y, Du J, Fan S, Pan B, Wang Y et al. miR-381 suppresses C/EBPα- dependent Cx43 expression in breast cancer cells. Biosci Rep 2015; 35: e00266.
147. Adams BD, Claffey KP, White BA. Argonaute-2 expression is regulated by epidermal growth factor receptor and mitogen-activated protein kinase signaling and correlates with a transformed phenotype in breast cancer cells. Endocrinology 2009; 150: 14-23.